psoriasis vulgaris
Conditions
Interventions
Group C:Control group (blood stasis syndrome) use placebo
Group E:Treatment group (blood stasis syndrome) use Huoxue
Group B:Treatment group (blood syndrome). Liangxuehuoxueta
Group D:Treatment group (blood dryness syndrome) use Yangxue Jiedu Tang
Group F:Control group (blood dryness syndrome) use placebo
Group A:Control group (blood dryness syndrome) use placebo
Sponsors
Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. be diagnosed as psoriasis vulgaris; 2. be diagnosed according to the unique TCM signs include "Xue Re" (blood heat), "Xue Zao" (blood dryness) and "Xue Yu" (blood stasis); 3. the lesional area<30% of body area; 4. 18 year to 65 year old; 5. Signed informed consent, voluntary subjects, and the informed process according to GCP requirements.
Exclusion criteria
Exclusion criteria: 1. Psoriasis arthropathica, psoriasis erythrodermic, and psoriasis pustulsoa; 2. Pregnancy or breast-feeding female; 3. Oral or topical administrating corticosteroids, immunosuppressant or retinoic acid drugs or vitamin D analogues in last month; 4. Associated with cardiovascular, cerebrovascular, hepatic, renal and hematopoietic system or psychotic diseases; 5. Allergic to the dugs; 6. Patients who are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| psoriasis area and severity index (PASI); | — |
Secondary
| Measure | Time frame |
|---|---|
| The main indicators of TCM clinical symptom; | — |
Countries
China
Contacts
Public ContactWang Jusheng
Outcome results
None listed